Wegovy Mental Health and Mood Impact: What the Clinical Evidence Actually Shows

What the Wegovy label lists as warnings

Section 5 of the Wegovy label covers thyroid C-cell tumors, acute pancreatitis, gallbladder disease, hypoglycemia with insulin or insulin secretagogues, acute kidney injury from volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications, heart rate increase, pulmonary aspiration during general anesthesia or deep sedation, and never sharing a FlexTouch pen [1]. The former suicidal behavior and ideation warning was removed from the label in 02/2026 and is not in the current text [1].

What the 2.4 mg trials list as adverse reactions

The label's adverse-reaction table pools three placebo-controlled trials of up to 68 weeks in adults with obesity or overweight: 2,116 people on Wegovy 2.4 mg and 1,261 on placebo [1]. The table lists reactions reported in at least 2% of Wegovy-treated adults and more often than with placebo: nausea 44% vs 16%; diarrhea 30% vs 16%; vomiting 24% vs 6%; constipation 24% vs 11%; abdominal pain 20% vs 10%; headache 14% vs 10%; fatigue 11% vs 5%; dyspepsia 9% vs 3%; dizziness 8% vs 4%; abdominal distension 7% vs 5%; eructation 7% vs <1%; flatulence 6% vs 4%; gastroenteritis 6% vs 4%; GERD 5% vs 3%; gastritis 4% vs 1%; hair loss 3% vs 1%; dysesthesia 2% vs 1% [1].

What the STEP trials reported

STEP 1 enrolled 1,961 adults without diabetes for 68 weeks: mean weight change was -14.9% with semaglutide 2.4 mg vs -2.4% with placebo [2]. STEP 5 followed 304 adults for 104 weeks: mean weight change was -15.2% vs -2.6%, with gastrointestinal adverse events in 82.2% vs 53.9% [3].

How semaglutide acts on appetite and reward circuits

Semaglutide is a GLP-1 receptor agonist that binds receptors in brain areas that regulate appetite and calorie intake, and it also delays gastric emptying [1]. In animal experiments, activating GLP-1 receptors in the ventral tegmental area and nucleus accumbens, part of the mesolimbic reward system, reduced food intake, especially of highly palatable food, and lowered body weight [4]. That is a finding about eating behavior in animals; it does not show that semaglutide blunts pleasure or mood in people.

What about antidepressants and other psychiatric medicines?

The label's drug-interaction section covers two things: insulin or insulin secretagogues, where hypoglycemia risk rises and a lower dose may be considered, and oral medicines, because Wegovy delays gastric emptying and may affect their absorption [1]. Levothyroxine exposure rose 33% with the semaglutide tablet in an interaction study, and the label advises considering closer monitoring for drugs with a narrow therapeutic index [1]. Antidepressants and lithium are not named in that section [1].